Lamotrigine

Expert Review of Neurotherapeutics

Volumn 1, Issue 1, 2001, Pages 33-42

  Willmore, L James ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Absence epilepsy; Epilepsy; Glutamate; Lamictal; Lamotrigine; Partial seizures; Rash; Valproate

Indexed keywords

ANTICONVULSIVE AGENT; ENZYME INDUCING AGENT; LAMOTRIGINE; VALPROIC ACID;

ADULT; AFFECTIVE NEUROSIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; NEUROPROTECTION; PAIN; PHASE 3 CLINICAL TRIAL; POSTMARKETING SURVEILLANCE; RASH; REVIEW;

EID: 0035741370     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.1.1.33     Document Type: Review

References (123)

1. Lamotrigine in primary generalised epilepsy
2. An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy
3. The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increased spontaneous GABA release in the rat entorhinal cortex in vitro
4. The effect of lamotrigine on epileptiform discharges in young patients with drug-resistant epilepsy
5. Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy
6. Lamotrigine, a new anticonvulsant: Pharmacokinetics in norman humans
7. Pharmacological studies on lamotrigine, a novel antiepileptic drug: I. Anticonvulsant profiles in mice and rats
8. Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects
9. Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy
10. Sodium valproate acutely inhibits lamotrigine metabolism
11. The effect of age on pharmacokinetics of antiepileptic drugs
12. Choice and use of newer anticonvulsant drugs in older patients
13. Adult experience with lamotrigine
14. Interaction of lamotrigine with sodium valproate
15. Clinical study of lamotrigine and valproic acid in patients with epilepsy: Using a drug interaction to advantage?
16. Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers
17. Single-dose pharmacokinetics of lamotrigine in children: Influence of age and antiepileptic comedication
18. Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs
19. Lamotrigine
20. Controlled trial of Lamotrigine (Lamictal) for refractory partial seizures
21. A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures
22. A randomized, double-blind, placebo-controlled, add-on trial of lamotrigine in patients with severe epilepsy
23. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures
24. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment resistant partial seizures
25. Lamotrigine therapy for partial seizures: A multicenter placebo-controlled, double-blind, crossover trial
26. Outcome of add-on treatment with lamotrigine in partial epilepsy
27. Overview of the clinical efficacy of lamotrigine
28. Clinical experience with lamogrigine (Lamictal) monotherapy for partial seizures in adult out-patients
29. Comparisone of lamotrigine (Lamictal) and phenytoin monotherapy in newly diagnosed epilepsy
30. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy
31. Lamotrigine versus carbamazepine: A double-blind comparative study in newly diagnosed epilepsy
32. Lamotrigine (Lamictal) versus carbamazepine as monotherapy in patients with epilepsy
33. An active-control trial of lamotrigine monotherapy for partial seizures
34. Efficacy of lamotrigine in add on controlled studies
35. Lamotrigine: Historical background
36. Safety review of adult clinical trial experience with lamotrigine
37. The tolerability of lamotrigine in children
38. The long-term use of vigabatrin and lamotrigine in patients with severe childhood onset epilepsy
39. Add-on lamotrigine treatment in children and young adults with severe partial epilepsy: An open, prospective long-term study
40. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children
41. Lamotrigine monotherapy in children
42. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome
43. Lamotrigine adjunctive therapy in childhood epileptic encephalopathy (the Lennox Gastaut syndrome)
44. Lamotrigine as an add-on drug in the management of Lennox-Gastaut syndrome
45. The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: A randomized, double-blind, crossover study
46. Lamotrigine and seizure aggravation in severe myoclonic epilepsy
47. Lamotrigine-induced severe cutaneous adverse reactions
48. Fatal toxic epidermal necrolysis related to lamotrigine administration
49. Stevens-Johnson syndrome associated with concomitant use of lamotrigine and valproic acid
50. Felbamate: 1997 Update
51. Adverse event monitoring in lamotrigine patients: A pharmacoepidemiologic study in the United Kingdom
52. Safety of long-term lamotrigine in epilepsy
53. Lamotrigine-associated rash: Risk/benefit consideratins in adults and children
54. Hypersensitivity reaction in a child due to lamotrigine
55. Lamotrigine-associated anticonvulsant hypersensitivity syndrome
56. Severe hypersensitivity syndrome to lamotrigine confirmed by lymphocyte stimulation in vitro
57. Metabolism of lamotrigine to a reactive arene oxide intermediate
58. Lamotrigine hypersensitivity in childhood epilepsy
59. Aggressive behavior in intellectually challenged patients with epilepsy treated with lamotrigine
60. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy
61. Lamotrigine associated with insomnia
62. Lamotrigine overdose in an adult
63. Lamotrigine childhood overdose
64. Fulminant hepatic failure induced by lamotrigine
65. Acute hepatic failure in a child treated with lamotrigine
66. Multisystem hypersensitivity reaction to lamotrigine
67. Multisystem adverse reaction to lamotrigine
68. Acute hepatitis after lamotrigine administration
69. Agranulocytosis associated with lamotrigine
70. Drug-induced pseudolymphoma secondary to lamotrigine
71. Exacerbation of juvenile myoclonic epilepsy with lamotrigine
72. Severe myoclonic epilepsy in infants
73. Disabling erratic myoclonus during lamotrigine therapy with high serum level-report of two cases
74. Myoclonic status epilepticus following high-dosage lamotrigine therapy
75. Lamotrigine attenuates cortical glutamate release during global cerebral ischaemia in pigs on cardiopulmonary bypass
76. Lamotrigine improves cerebral outcome after hypothermic circulatory arrest: A study in chronic porcine model
77. Effect of neuronal sodium channel blocker on magnetic resonance derived indices of brain water content during global cerebral ischaemia
78. Neuroprotective effects of lamotrigine enhanced by flunarizine in gerbil global ischaemia
79. Neuroprotective effect of lamotrigine and MK-801 on rat brain lesions induced by 3-nitropropionic acid: Evaluation by magnetic resonance imaging and in vivo proton magnetic resonance spectroscopy
80. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures
81. Valproate therapy for prevention of posttraumatic seizures: A randomized trial
82. Lamotrigine treatment during amygdala-kindled sezizure development fails to inhibit seizures and diminishes subsequent anticonvuslant activity
83. Treatment of typical absence seizures and related epileptic syndromes
84. Lamotrigine as an add-on drug in typical absence seizures
85. Lamotrigine in typical absence epilepsy
86. Lamictal (lamotrigine) monotherapy for typical absence seizures in children
87. Optimal use of lamotrigine in clinical practice: Results of an open multicenter trial in refractory epilepsy
88. Long-term retention rates of lamotrigine, gabapentin and topiramate in chronic epilepsy
89. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: Evidence for a pharmacodynamic interaction
90. Adding lamotrigine to valproate: Incidence of rash and other adverse effexts
91. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy
92. Prospective, open-label, add-on study of lamotrigine in 56 children with intractable generalized epilepsy
93. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: A double-blind comparison with phenytoin
94. Differential cognitive and behavioral effects of carbamazepine and lamotrigine
95. Cognitive effects of topiramate, gabapentin and lamotrigine in healthy young adults
96. Lamotrigine: A review of clinical studies in bipolar disorders
97. Novel treatments for bipolar disorder
98. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders
99. A double-blind,placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder
100. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder
101. Stimulating consciousness and cognition following severe brain injury: A new potential clinical use for lamotrigine
102. A preliminary investigation of lamotrigine for cocaine abuse in HIV-seropositive patients
103. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: An open pilot study
104. Lamotrigine in the prophylactic treatment of migraine aura - A pilot study
105. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura
106. A randomized open-label study of gabapentin and lamotrigine in adults with learning disability and resistant epilepsy
107. Lamotrigine in two cases of Rett syndrome
108. New generation antiepileptics for facial pain and headache
109. Lamotrigine (lamictal) in refractory trigeminal neuralgia: Results from a double-blind placebo-controlled crossover trial
110. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy
111. Two new SUNCT cases responsive to lamotrigine
112. Lamotrigine for central poststroke pain: A randomized controlled trial
113. The teratogenicity of anticonvulsant drugs
114. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: A pharmaceutical company commitment
115. Lamotrigine in pregnancy: Pharmacokinetics during delivery, in the neonate and during lactation
116. Lamotrigine in pregnancy and lactation: A case report
117. Acute granulomatous interstitial nephritis and colitis in anticonvulsant hypersensitivity syndrome associated with lamotrigine
118. Lupus anticoagulant induced by the combination of valproate and lamotrigine
119. Successful treatment of lamotrigine-induced erythroblastopenic crisis with folinic acid
120. Lamotrigine-induced lupus
121. Lamotrigine-induced tic disorder: Report of five pediatric cases
122. Lamotrigine-induced tourettism